Extended Data Table 2 Demographics and baseline characteristics of patients entering the SBTP

From: Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

  1. aTime from diagnosis to study randomization. bIncludes omega-3-acid ethyl ester, omega-3 fatty acids, eicosapentaenoic acid ethyl ester, ezetimibe, fish oil, combination of docosahexaenoic acid, eicosapentaenoic acid and fish oil, eicosapentaenoic acid and omega-3 triglycerides. BMI, body mass index; CHD, coronary heart disease; DB, double blind; GLP-1, glucagon-like peptide-1; IV, intravenous; Q4W, every 4 weeks; SD, standard deviation; SGLT2, sodium glucose co-transporter 2
Back to article page